* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Collegium Pharmaceutical Forward PE Ratio Chart
Collegium Pharmaceutical Annual Data
Trend
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
Forward PE Ratio
109.89
27.93
4.78
4.45
4.62
4.03
4.43
Collegium Pharmaceutical Quarterly Data
2018-09
2018-12
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
Forward PE Ratio
147.06
109.89
21.41
27.93
4.48
4.55
5.07
4.78
5.68
7.33
4.87
4.45
3.91
3.76
3.26
4.62
4.31
4.10
3.51
4.03
6.28
5.13
5.71
4.43
Competitive Comparison of Collegium Pharmaceutical's Forward PE Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical's Forward PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Forward PE Ratio falls into.
Collegium Pharmaceutical Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Collegium Pharmaceutical (NAS:COLL) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Collegium Pharmaceutical Forward PE Ratio Related Terms
Thank you for viewing the detailed overview of Collegium Pharmaceutical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COLL has been successfully added to your